Oruka Therapeutics, Inc. (ORKA) on Monday announced positive interim data from its Phase 1 trial of ORKA-002.
The study, conducted in healthy volunteers, evaluated the safety and pharmacokinetics of the drug. Interim results showed a half-life of 75-80 days, supporting the potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa. ORKA-002 was well tolerated at all dose levels, with no severe or serious treatment-emergent adverse events reported.
Phase 2 studies for ORKA-002 are expected to begin in the first half of 2026 in psoriasis and the second half of 2026 in hidradenitis suppurativa.
Meanwhile, a Phase 2b study of ORKA-001 dubbed EVERLAST-B is underway with data expected in 2027.
On Friday, Oruka shares closed at $27.86, up 5.53%.
For comments and feedback contact: editorial@rttnews.com
Business News
January 09, 2026 15:02 ET U.S. external trade data and labor market figures were in focus this week as the news flow gained momentum in the new year. In Europe, inflation data for the euro area was the highlight. The single-currency bloc expanded to 21 countries this year with Bulgaria adopting the currency on January 1. News flow in Asia was dominated by the survey data on the Chinese services industry.